Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. And retail traders should know. We ...

Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, leading to a rise ...

Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug ...

Eli Lilly (LLY) stock is rising after the company said its weight-loss drug achieved better results than Wegovy ...

Tiger Global Management's 13F portfolio increased to $23.44B. Check out the notable increases, decreases, and new stakes of ...

Eli Lilly & Co. Inc.’s stock LLY rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective ...

Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made available to around 220,000 people in the country via the state health ...

Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...

Though the pharmaceutical giant isn't performing as well in the second half of the year as it did in the first, it still has ...

Navitas Semiconductor is losing money according to Jim Cramer. LandBridge Company is a winner, while Regeneron is facing ...

Investing.com -- Eli Lilly said Wednesday that its weight-loss medication Zepbound (tirzepatide) demonstrated superior efficacy over Novo Nordisk (NYSE: NVO )'s Wegovy (semaglutide) in the phase 3b ...

EST Lilly says Zepbound superior to Novo’s Wegovy weight loss in head-to-head trial Published first on TheFly – the ultimate source for ...